Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

‘Promising’ durvalumab results spark phase 3 trial in mesothelioma

Key clinical point: Adding durvalumab to first-line pemetrexed and cisplatin improved survival in patients with unresectable malignant pleural mesothelioma, compared with historical controls who received only pemetrexed and cisplatin.

Major finding: The median overall survival was 20.4 months in patients who received durvalumab plus pemetrexed-cisplatin in a phase 2 trial and 12.1 months in patients who received only pemetrexed-cisplatin in a prior study (P = .0014).

Study details: A phase 2 study of 55 patients, compared with a historical control group of 226 patients from a phase 3 trial.

Disclosures: AstraZeneca, maker of durvalumab, funded the phase 2 study. Investigators reported various ties to the company.

Citation:

Forde PM et al. ASCO 2020, Abstract 9003; Vogelzang NJ et al. J Clin Oncol. 2003 Jul 15;21(14):2636-44.